M
Mark M. Davis
Researcher at Stanford University
Publications - 623
Citations - 84251
Mark M. Davis is an academic researcher from Stanford University. The author has contributed to research in topics: T cell & T-cell receptor. The author has an hindex of 144, co-authored 581 publications receiving 74358 citations. Previous affiliations of Mark M. Davis include Washington University in St. Louis & University of Chicago.
Papers
More filters
Journal ArticleDOI
The adult T-cell receptor delta-chain is diverse and distinct from that of fetal thymocytes.
John F. Elliott,Edwin P. Rock,Phillip A. Patten,Phillip A. Patten,Mark M. Davis,Mark M. Davis,Yueh-hsiu Chien +6 more
TL;DR: A large number of δ-containing complementary DNA clones from adult double-negative thymocytes are characterized, an immature population that is enriched for γδ-bearing cells5 and finds that a limited number of Vδ sequences are used, showing little overlap with known adult Vαs and differing significantly from fetal Vεs.
Journal ArticleDOI
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts
Rutger-Jan Swijnenburg,Sonja Schrepfer,Johannes A. Govaert,Feng Cao,Katie Ransohoff,Ahmad Y. Sheikh,Munif Haddad,Andrew J. Connolly,Mark M. Davis,Robert C. Robbins,Joseph C. Wu +10 more
TL;DR: It is shown that immunosuppressive drug regimens can mitigate the anti-hESC immune response and that a regimen of combined tacrolimus and sirolimus therapies significantly prolongs survival of hESCs for up to 28 days.
Ligand recognition by t cell receptors
Mark M. Davis,J. Jay Boniface,Ziv Reich,Daniel S. Lyons,Johannes Hampl,Bernhard Arden,Yueh-hsiu Chien +6 more
TL;DR: An analysis of the highly diverse CDR3 loops found in all antigen receptor molecules is concluded and it is suggested that such regions form the core of both TCR and antibody specificity.
Journal ArticleDOI
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Leo Swadling,Stefania Capone,Richard D Antrobus,Anthony Brown,Rachel Richardson,Evan W. Newell,Evan W. Newell,John Halliday,John Halliday,Christabel Kelly,Christabel Kelly,Dan Hameiri Bowen,Joannah R. Fergusson,Ayako Kurioka,Virginia Ammendola,Mariarosaria Del Sorbo,Fabiana Grazioli,Maria Luisa Esposito,Loredana Siani,Cinzia Traboni,Adrian V. S. Hill,Stefano Colloca,Mark M. Davis,Alfredo Nicosia,Riccardo Cortese,Antonella Folgori,Paul Klenerman,Paul Klenerman,Eleanor Barnes,Eleanor Barnes +29 more
TL;DR: A first-in-human trial of a prime-boost vaccine strategy for HCV, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine.
Journal Article
Frequency of Class I HLA-Restricted Anti-HIV CD8+ T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART)
Clive M. Gray,Jody Lawrence,Jonathan M. Schapiro,John D. Altman,John D. Altman,Mark A. Winters,Meg Crompton,Muoi Loi,Smriti K. Kundu,Mark M. Davis,Thomas C. Merigan +10 more
TL;DR: Evidence is provided that persistently replicating viral populations are probably required to maintain high frequencies of HIV-1 epitope-specific CD8+ T cells in asymptomatic chronically infected individuals.